OAS-19 / Vivesto - LARVOL DELTA

Long-term Follow-Up of Pheochromocytoma/Paraganglioma (PPGL) after first diagnosis: a retrospective single-center study of 173 patients) (ENDO 2022) - "5 of these 37 (13.5%), and 7 of 57 (12%) mutation-negative (MN-PPGL, mean±SD age 53.3±14.8 years, p<0.01 vs. MP-PPGL, OAS 190 months) died during FU (p=0.03)... The cohort of our study is the third-largest original report on long-term FU and prognostic markers in PPGL. While others (Ayola-Ramirez et al, JECM 2011) in 371 patients found tumor size and sympathetic PGL independently associated with OAS, we did not. Patients may have harbored more aggressive tumors in that study, as higher primary metastatic spread (25% of Pheos, 60% of sympathetic PGL) was identified."

Retrospective data • Adrenal Cortex Carcinoma • Cardiovascular • Endocrine Cancer • Neuroendocrine Tumor • Oncology • Solid Tumor

"@StevenMay66 @TopMaxLord @ublach @GTan333 @Brianjensor @newz77 @TFREMON @tkane163 @MARCO_REYES619 @doas1959 @5stringplyr @katrinaboykin2 @Lgreenteam @JoyceScar03 @randall1194 @JayHarr78761191 @abstractpapashv @Chardiongrrr @SimonHermans @AngeliaJerrie" (@OnnurTemiz)

"What a privilege to have @jesse8850 at #SOASS19 for the Leonard Horowitz Memorial Lecture @DavidCallans @DrFerminGarcia @EricaZado @CMTschabrunn" (@Dr_Santangeli)